I was impressed by this first study of dabrafenib in pediatric patients with BRAF V600E–mutated relapsed, refractory low-grade glioma.— Guido Reifenberger, MD
“Low-grade gliomas are biologically and clinically heterogeneous entities with different genetic drivers,” said formal discussant of this trial, Guido Reifenberger, MD, of Heinrich Heine University, Düsseldorf, Germany.
“The BRAF V600 mutation is a novel therapeutic target in gliomas occurring in a subset of tumors. Anecdotal evidence and case reports suggest that BRAF inhibitors that target the V600E mutation are effective. I was impressed by this first study of dabrafenib in pediatric patients with BRAF V600E–mutated relapsed, refractory low-grade glioma,” Dr. Reifenberger told listeners.
“This was only a one-arm study, but these are promising data from the first prospective study of dabrafenib in this subgroup of pediatric patients,” he said. ■
Disclosure: Dr. Reifenberger has received research grants from Roche and Merck.
About 10% of children with low-grade gliomas have the BRAF V600E mutation, and preliminary studies suggest that the BRAF inhibitor dabrafenib (Tafinlar) may play an important role in treating this group of patients. A phase I/II trial presented at the 2016 European Society for Medical Oncology...